Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR

Patients with Fabry disease present a higher risk of cardiovascular and kidney morbidity. We present a patient with a past history of biopsy-proven Fabry disease and stage 3 chronic kidney disease. Proteinuria partially dropped from 6.8 g/day to 2.1 g/day despite an aggressive regime which consisted...

Descripción completa

Detalles Bibliográficos
Autores principales: Trimarchi, H., Forrester, M., Lombi, F., Pomeranz, V., Raña, M. S., Karl, A., Andrews, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052478/
https://www.ncbi.nlm.nih.gov/pubmed/24959362
http://dx.doi.org/10.1155/2014/854521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052478/
https://www.ncbi.nlm.nih.gov/pubmed/24959362
http://dx.doi.org/10.1155/2014/854521

Ejemplares similares